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FULLY INTERMITTENT SIX MONTH REGIMENS FOR PULMONARY
TUBERCULOSIS IN SOUTH INDIA*
Rani Balasubramanian
Summary : A large-scale multi-centric study in
South India was organised by the Tuberculosis
Research Centre, Madras. The regimens
c o n s i s t e d  o f Rifampicin, Isoniazid,
Streptomycin and Pyrazinamide, administered
under supervision, twice or thrice a week for
the first 2 months, followed by different
combinations of 2 or 3 drugs administered
twice or once a week for the next 4 months. The
patients were followed up with intensive
bacteriological examination. The response at
the end of chemotherapy and the relapse rates
during a 4½-year follow-up in approximately
1,000 patients with drug-sensitive organisms
initially and 200 patients with organisms
initially drug resistant are presented.
Introduction
The earlier studies from the Tuberculosis
Research Centre, Madras, have shown that Short
Course Chemotherapy regimens of 5 to 7 months’
duration are effective in sputum positive
pulmonary tuberculosis. However, there are
some limitations, e.g. high incidence of arthralgia
and hepatitis in daily chemotherapy and patients
having to attend daily for a period of 2 to 3
months. The alternative is to try out fully
intermittent chemotherapy, as intermittent
regimens are likely to be less toxic. Hence, we
undertook a controlled clinical study of 10 fully
intermittent regimens of different rhythms in
initial phase and various drug combinations and
rhythm in continuation phase.
Material and Methods
The present paper incorporates the findings in
patients during a follow up period of 54 months
after stopping chemotherapy.
The criteria for admission were as follows :
Patients had to be bona fide residents of Madras
or Tambaram, aged 12 years or more. They had
not had more than 6 months of previous anti-
tuberculosis chemotherapy and had two smears
positive for AFB.Patients did not have
concomitant renal or hepatic or cardiac disease
or diabetes mellitus.
The regimens employed were as follows :
Streptomycin + Rifampicin + Isoniazid +
Pyrazinamide administered either twice or thrice
a week during initial phase for two months,
followed by either Rifampicin and Isoniazid twice
weekly with orwithout Streptomycin or
Rifampicin and Isoniazid once weekly with or
without SM or Streptomycin + Isoniazid twice
Chart 1.
Initial (2M) Continuation (4M)
SRHZ3 (Thrice weekly) RH2, SRH2 (Twice weekly),
OR RH1, SRH1 (Once weekly).
SRHZ2 (Twice weekly) SH2 (Twice weekly),
weekly for 4 months. Patients were allocated at
random to one of the ten regimens shown below.
The dosages of drugs were as shown below :
Chart 2.
Drugs
Streptomycin (S)
Rifampicin (R)
Isoniazid (H)
Pyrazinamide (P)
Dosage
0.75 gm
12 mg/kg
15 mg/kg*
50 mg/kg
Thrice Weekly
70 mg/kg
Twice Weekly
* Incorporating Pyridoxine 10 mg
* Paper presented at the 45th National Conference on TB and Chest Diseases held at Rohtak in January, 1991.
Correspondence:Dr. Rani Balasubramanian, TB Research Centre, Spurtank Road, Chetput, Madras-600 031.
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A total of 1,157 patients were admitted to the
study. Of these, 81% had organisms sensitive to
Streptomycin, Rifampicin and Isoniazid. Only 4
of the 937 drug sensitive patients had
unfavourable response. All the others with
favourable response, i.e. negative cultures in the
last two months, were followed up for a period of
54 months after stopping treatment.
Investigations during follow up included two
sputum specimens monthly from 7 to 24 months,
three sputum specimens six monthly from 25 to
60 months and chest X-ray annually from 12 to 60
months.
Bacteriological relapse requiring treatment
was defined as a total of two or more positive
cultures in three consecutive months, at least one
with 20 colonies or more and accompanied by at
least one positive smear.
Results
The bacteriological response in drug sensitive
patients is presented in Table 1. Considering
thrice weekly series, the proportion of patients
who had relapsed varied from 5% to 7%, the
average being 6.2%. In the twice weekly series, it
was either 7% or 8% in all except the regimen
where Streptomycin & Isoniazid were given twice
a week in the follow up phase, where it was 12%.
The difference between this and others is not
statistically significant. The relapse rates of all the
10 regimens are similar indicating that all are of
equal efficacy in patients with sensitive drug
organisms irrespective of the differences in the
rhythm in the initial phase or number of drugs,
that is two or three drugs or rhythm either twice a
week or once a week.
Table 1. Bacteriological relapse in drug sensitive patients
Initial 2 M
Conti- SRHZ3 SRHZ2
Total Relapse
4M patients % patients %
S R H2 9 0 6 89 7
RH2 94 7 90 8
S R H1 9 9 6 6.2 103 7 7.9
RH1 96 5 92 7
SH2 89 7  95 12
* Upto 54 Months after stopping treatment
T  findings in patients with initial resistance
to H or SH are shown in Table 2. Resistance to
Streptomycin alone does not pose a problem  
when patients are treated with short course
chemotherapeutic regimens. The unfavourable
response and overall failure rates are given
according to the drugs in continuation phase. The
results of thrice weekly and twice weekly series
during initial phase are similar and have,
therefore, been combined and presented here.
Considering the regimen where SRH2 was given
in continuation phase, the proportion of patients
who had unfavourable response was 17% of 36
patients and overall failure rate was 17%. When
the same drugs were given without Streptomycin,
the u favourable response occurred in 19% of 26
patients similar to the regimen containing
Streptomycin and the overall failure rate was
23% similar to 17%. In contrast, when the same 3
drugs were given once a week, unfavourable
response occurred in 30% of 30 patients, the
proportion was significantly higher(X2 = 5.62 for
1 df P < 0.02) than the regimen where drugs were
Table 2. Findings in patients with initial resistance to H
or SH
Drugs in Total Unfavourable
continuation patientsresponse
phase No %
SRH2 36* 17*
Overall
failure**
%
17
19%
RH2 26 19 23
SRH1 30 30 47
46%
RH1 27 41 44
SH2 34 59
74
* Initial resistance to RMP in one patient
** Failure (unfavourable response + relapse)
given twice a week and the overall failure rate
increased to 47%. And when the same drugs were
given without Streptomycin, the failure rate was
44% similar to the regimen where Streptomycin
was given in addition. The difference between
46% and 19% is statistically significant. Coming
to the regimen where no Rifampicin was given in
continuation phase,unfavourable response
increased to 59% of 34 patients and failure rate
also increased to 74%, a significantly higher
proportion than the other 4 regimens. The
differences between 74% and 46% (X2 = 5.65 for
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1 df, P = 0.02) and 74% and 19% (X2 = 25.0 for 1
df P < 0.001) are highly significant. There was
one patient in SRH, series who had initial
Rifampicin resistance, and he had unfavourable
response.These findings clearly indicate that
Rifampicin is essential in treatment of patients
with initial drug resistance to H or SH and the
response is much better in patients treated with
regimens where Rifampicin is given throughout
the period of 6 months compared to regimens
where Rifampicin is given only during the initial
period of 2 months. Among 6 month Rifampicin
regimens, there was better response in patients
treated with Rifampicin twice a week than among
those given once a week. Streptomycin as a third
drug in continuation phase has no additional
benefit.
To conclude, fully intermittent 6-month
regimens are effective in patients with organisms
sensitive to anti-tuberculous drugs. In patients
wi  organisms resistant to anti-tuberculous
drugs, lower failure rates were observed in 6
months’ Rifampicin regimen compared to 2
months’ Rifampicin regimen. Among 6 months
Rifampicin regimens,better rjesponse was
obtained with Rifampicin and Isoniazid given
twice a week than once a week. Streptomycin as a
third drug in continuation phase has no additional
benefit.
